Isaura Santos,  —

ieCrowd™ recently announced the achievement of a crucial milestone in the commercial advancement of Smart Oxygen, the firm’s supplemental oxygen delivery device. The Smart Oxygen device is being advanced by ieCrowd’s subsidiary Smart Oxygen Solutions and has the ability to automatically adjust to the patient’s need for oxygen, even if those demands are constantly changing, through analyzing the level of…

Entra Health has recently announced the launch of Entra360, a novel solution for easily and effectively implementing wireless biometric data. Entra360 is a particularly innovative solution for both the payer or provider, as well as the COPD clinical research market. Entra360 is one of several efforts the company is making to provide easy-to-implement solutions to allow remote…

The ACI Association recently compiled a report on Aquinox Pharmaceuticals Inc. based on the company’s internal reports to make them available to the general public. Aquinox is currently developing AQX-1125, an investigational therapy for COPD, which was recently evaluated in a phase 2 clinical trial called FLAGSHIP. Aquinox announced recently that its FLAGSHIP…

After several successful events covering respiratory disease research and drug development, SMi’s conference on COPD will be held again this year in Central London. Now in its seventh consecutive year, SMi’s COPD conference is scheduled for the 19th and 20th October. Sponsored by Quintiles, a leading biotech CRO, this year’s conference will feature an exclusive post-conference event as…

COPD is a major global public heath issue. According to a study in the Lancet, 329 million people have COPD worldwide, which accounts for nearly 5% of the world’s population. In 2013 alone, 2.9 million people died from the disease throughout the world, up from 2.4 million deaths…

Chronic obstructive pulmonary disease (COPD) is one of the most frequent causes of death worldwide and active smoking is responsible for almost 85 percent of all cases. However, recent research from the University of Copenhagen shows that accelerated decline of lung function might not be a prerequisite for COPD. The results were recently published in the New England…

The COPD Foundation has announced that plasma fibrinogen, a new clinical biomarker, was approved to be used in interventional clinical trials for those suffering with chronic obstructive pulmonary disease (COPD), the number 3 cause of death in the country. This is the first biomarker for COPD to receive qualification from the United States Food…

According to a recent study published in The BMJ, new guidelines to diagnose chronic lung disease (chronic obstructive pulmonary disease or COPD) should be modified since they under-diagnose COPD in young women and over-diagnose COPD in older men. Martin Miller and Dr. Mark Levy, authors of the article, noted that up…

Computed tomography (CT) and magnetic resonance imaging (MRI) provide relevant information about the symptoms and exercise capabilities of those suffering with mild-to-moderate chronic obstructive pulmonary disease (COPD), a finding that was recently published in the Radiology journal that could lead to new and better treatments for COPD patients. COPD, a progressive disease of the…